These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3568326)

  • 1. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction.
    Francis CW; Connaghan DG; Scott WL; Marder VJ
    Circulation; 1987 Jun; 75(6):1170-7. PubMed ID: 3568326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.
    Connaghan DG; Francis CW; Lane DA; Marder VJ
    Blood; 1985 Mar; 65(3):589-97. PubMed ID: 3971042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.
    Francis CW; Connaghan DG; Marder VJ
    Circulation; 1986 Nov; 74(5):1027-36. PubMed ID: 3533310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII.
    Greenberg CS; Achyuthan KE; Rajagopalan S; Pizzo SV
    Arch Biochem Biophys; 1988 Apr; 262(1):142-8. PubMed ID: 2895608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.
    Greenberg CS; Miraglia CC; Rickles FR; Shuman MA
    J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers.
    Francis CW; Doughney K; Brenner B; Klingbiel K; Marder VJ
    Circulation; 1989 Mar; 79(3):666-73. PubMed ID: 2465100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of fibrin polymers on thrombin-catalyzed plasma factor XIIIa formation.
    Greenberg CS; Miraglia CC
    Blood; 1985 Aug; 66(2):466-9. PubMed ID: 2861869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders.
    Kornberg A; Francis CW; Marder VJ
    Blood; 1992 Aug; 80(3):709-17. PubMed ID: 1386260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gly-Pro-Arg-Pro modifies the glutamine residues in the alpha- and gamma-chains of fibrinogen: inhibition of transglutaminase cross-linking.
    Achyuthan KE; Dobson JV; Greenberg CS
    Biochim Biophys Acta; 1986 Aug; 872(3):261-8. PubMed ID: 2873839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
    Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
    Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective alpha-polymerization in the conversion of fibrinogen Baltimore to fibrin.
    Brown CH; Crowe MF
    J Clin Invest; 1975 Jun; 55(6):1190-4. PubMed ID: 1133167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in clot deformability--a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction.
    Scrutton MC; Ross-Murphy SB; Bennett GM; Stirling Y; Meade TW
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):719-23. PubMed ID: 7865677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific identification of fibrin(ogen) degradation products in plasma and serum using blotting and peroxidase labeled antiserum.
    Proietti AB; McGuire M; Bell W
    Am J Hematol; 1990 Aug; 34(4):270-4. PubMed ID: 2195868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen Houston: a dysfibrinogen exhibiting defective fibrin monomer aggregation and alpha-chain cross-linkages.
    Weinger RS; Rudy C; Moake JL; Conlon CL; Cimo PL
    Am J Hematol; 1980; 9(3):237-48. PubMed ID: 6165239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of plasma factor XIII binding to fibrin in vitro.
    Greenberg CS; Dobson JV; Miraglia CC
    Blood; 1985 Nov; 66(5):1028-34. PubMed ID: 2413926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent crosslinking of von Willebrand factor to fibrin.
    Hada M; Kaminski M; Bockenstedt P; McDonagh J
    Blood; 1986 Jul; 68(1):95-101. PubMed ID: 2872929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)].
    Klingemann HG; Brunswig D; Liehr H
    Z Gastroenterol; 1978 Sep; 16(9):564-73. PubMed ID: 706517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and clinical implications of heparin-associated false positive tests for serum fibrin(ogen) degradation products.
    Connaghan DG; Francis CW; Ryan DH; Marder VJ
    Am J Clin Pathol; 1986 Sep; 86(3):304-10. PubMed ID: 3751995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clottability and cross-linking reactivity of fibrin(ogen) following differential release of fibrinopeptides A and B.
    Furlan M; Seelich T; Beck EA
    Thromb Haemost; 1976 Dec; 36(3):582-92. PubMed ID: 14415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Course of indicators of thrombin activity in the early phase of acute myocardial infarction: effect of fibrinolytic therapy and acute percutaneous coronary angioplasty.
    Dempfle CE; Kaden JJ; Haase KK; Borggrefe M
    Thromb Haemost; 2003 Jul; 90(1):147-54. PubMed ID: 12876638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.